Stockreport

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Gu...

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF cancer therapies, today announced that its proprietary CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a rec [Read more]